WARNING: This product is for research use only, not for human or veterinary use.

MedKoo CAT#: 412392

CAS#: 68020-77-9

Description: Carprazidil is a vasoactive antihypertensive agent which does not produce tachycardia or water & sodium retention.

Chemical Structure

CAS# 68020-77-9

Theoretical Analysis

MedKoo Cat#: 412392
Name: Carprazidil
CAS#: 68020-77-9
Chemical Formula: C12H13N5O4
Exact Mass: 291.0968
Molecular Weight: 291.27
Elemental Analysis: C, 49.48; H, 4.50; N, 24.04; O, 21.97

Price and Availability

This product is not in stock, which may be available by custom synthesis. For cost-effective reason, minimum order is 1g (price is usually high, lead time is 2~3 months, depending on the technical challenge). Quote less than 1g will not be provided. To request quote, please email to sales or click below button.
Note: Price will be listed if it is available in the future.

Request quote for custom synthesis

Synonym: Carprazidil; Carprazidilum; UNII-O55EMK06L9

IUPAC/Chemical Name: Carbamic acid, (5-(3,6-dihydro-1(2H)-pyridinyl)-2-oxo-2H-(1,2,4)oxadiazolo(2,3-a)pyrimidin-7-yl)-, methyl ester


InChi Code: InChI=1S/C12H13N5O4/c1-20-11(18)14-9-7-8(16-5-3-2-4-6-16)13-10-15-12(19)21-17(9)10/h2-3,7H,4-6H2,1H3,(H,14,18)


Appearance: Solid powder

Purity: >98% (or refer to the Certificate of Analysis)

Shipping Condition: Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.

Storage Condition: Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).

Solubility: Soluble in DMSO

Shelf Life: >3 years if stored properly

Drug Formulation: This drug may be formulated in DMSO

Stock Solution Storage: 0 - 4 C for short term (days to weeks), or -20 C for long term (months).

HS Tariff Code: 2934.99.9001

Preparing Stock Solutions

The following data is based on the product molecular weight 291.27 Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.

Recalculate based on batch purity %
Concentration / Solvent Volume / Mass 1 mg 5 mg 10 mg
1 mM 1.15 mL 5.76 mL 11.51 mL
5 mM 0.23 mL 1.15 mL 2.3 mL
10 mM 0.12 mL 0.58 mL 1.15 mL
50 mM 0.02 mL 0.12 mL 0.23 mL

Molarity Calculator

Calculate the mass, volume, or concentration required for a solution.

*When preparing stock solutions always use the batch-specific molecular weight of the product found on the vial label and SDS / CoA (available online).

Reconstitution Calculator

The reconstitution calculator allows you to quickly calculate the volume of a reagent to reconstitute your vial. Simply enter the mass of reagent and the target concentration and the calculator will determine the rest.


Dilution Calculator

Calculate the dilution required to prepare a stock solution.

1: Bianchetti MG, Weidmann P, Boehringer K, Link L, Schiffl H, Beretta-Piccoli C, Colombo JP. Comparative evaluation of the new vasodilator carprazidil and minoxidil in the treatment of moderate to severe hypertension. Eur J Clin Pharmacol. 1982;23(6):483-9. doi: 10.1007/BF00637493. PMID: 7160416.

2: Gerber A, Weidmann P, Saner R, Bianchetti M, Zbinden R, Link L, Riesen W, Mordasini R. Increased serum high-density lipoprotein cholesterol in hypertensive men treated with the potent vasodilator carprazidil. Metabolism. 1984 Apr;33(4):342-6. doi: 10.1016/0026-0495(84)90196-3. PMID: 6708817.

3: Weidmann P, Ferrier C, Saxenhofer H, Uehlinger DE, Trost BN. Serum lipoproteins during treatment with antihypertensive drugs. Drugs. 1988;35 Suppl 6:118-34. doi: 10.2165/00003495-198800356-00017. PMID: 3042351.

4: Weidmann P, Gerber A, Mordasini R. Effects of antihypertensive therapy on serum lipoproteins. Hypertension. 1983 Sep-Oct;5(5 Pt 2):III120-31. doi: 10.1161/01.hyp.5.5_pt_2.iii120. PMID: 6138309.

5: Glueck CJ. Nonpharmacologic and pharmacologic alteration of high-density lipoprotein cholesterol: therapeutic approaches to prevention of atherosclerosis. Am Heart J. 1985 Nov;110(5):1107-15. doi: 10.1016/0002-8703(85)90225-x. PMID: 2865887.

6: Gerold M, Eigenmann R, Hefti F, Daum A, Haeusler G. Cardiovascular effects of a novel vasoactive antihypertensive agent, Ro 12-4713. J Pharmacol Exp Ther. 1981 Mar;216(3):624-33. PMID: 7009831.

7: Cocco G, Strozzi C, Padula A, Al Yassini K, Bulgarelli R, Sfrisi C, Zaniol P. Vasodilator treatment for mild to moderate heart failure. Effect of Ro 12-4713, a minoxidil analogue. Cardiology. 1984;71(4):184-9. doi: 10.1159/000173663. PMID: 6478464.

8: Strozzi C, Cocco G, Tasini MT, Padula A, Rizzo A, Alfiero R, Urso L, Montanari L, Portaluppi F. Effetti della nifedipina e di un vasodilatatore arterioso minoxidil-simile sull'ischemia miocardica al controllo elettrocardiografico dinamico [Effects of nifedipine and a minoxidil-like arterial vasodilator on myocardial ischemia under dynamic electrocardiographic monitoring]. Clin Ter. 1986 Jul 15;118(1):9-12. Italian. PMID: 3742977.

9: Grimm M, Weidmann P, Meier A, Ziegler WH, Reubi FC. Acute effects of a new vasodilator, Ro 12-4713, on blood pressure, plasma Renin activity, Aldosterone and Catecholamine levels, and renal function in hypertensive and normal subjects. Eur J Clin Pharmacol. 1981;20(3):169-77. doi: 10.1007/BF00544594. PMID: 7026257.

10: Chu D, Cocco G, Strozzi C, Vallini R, Nonato M, Amrein R. Antihypertensive effects of a novel peripheral vasodilator, Ro 12-4713. Eur J Clin Pharmacol. 1981 Mar;19(4):233-8. doi: 10.1007/BF00562798. PMID: 7286027.